BidaskClub upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a buy rating to a strong-buy rating in a research report report published on Friday.

Several other analysts also recently commented on the company. Morgan Stanley upgraded Sarepta Therapeutics from an equal weight rating to an overweight rating and set a $163.00 target price for the company in a research note on Wednesday, August 1st. HC Wainwright set a $267.00 price target on Sarepta Therapeutics and gave the company a buy rating in a research note on Thursday, August 9th. Citigroup started coverage on Sarepta Therapeutics in a research note on Tuesday, August 14th. They set a buy rating for the company. Cowen reiterated a buy rating and set a $178.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, August 9th. Finally, Credit Suisse Group started coverage on Sarepta Therapeutics in a research note on Thursday, September 6th. They set an outperform rating and a $178.00 price target for the company. Three research analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and two have assigned a strong buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $154.21.

Shares of SRPT opened at $152.35 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 10.88 and a quick ratio of 9.89. The stock has a market capitalization of $10.02 billion, a PE ratio of -91.38 and a beta of 1.30. Sarepta Therapeutics has a one year low of $42.97 and a one year high of $176.50.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, August 8th. The biotechnology company reported ($1.67) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.99). The firm had revenue of $73.53 million during the quarter, compared to analyst estimates of $71.53 million. Sarepta Therapeutics had a negative net margin of 89.64% and a negative return on equity of 19.34%. The business’s quarterly revenue was up 110.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.48) earnings per share. sell-side analysts forecast that Sarepta Therapeutics will post -3.69 earnings per share for the current fiscal year.

In other Sarepta Therapeutics news, Director Richard Barry sold 75,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, June 27th. The shares were sold at an average price of $130.34, for a total transaction of $9,775,500.00. Following the transaction, the director now owns 3,170,432 shares of the company’s stock, valued at approximately $413,234,106.88. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Alexander Cumbo sold 33,782 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, July 9th. The stock was sold at an average price of $137.32, for a total transaction of $4,638,944.24. Following the transaction, the senior vice president now directly owns 40,690 shares in the company, valued at approximately $5,587,550.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 158,782 shares of company stock worth $21,237,444. Insiders own 7.90% of the company’s stock.

Several institutional investors have recently bought and sold shares of the business. Xact Kapitalforvaltning AB lifted its position in shares of Sarepta Therapeutics by 5.7% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 9,202 shares of the biotechnology company’s stock worth $1,216,000 after buying an additional 500 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of Sarepta Therapeutics by 2.7% during the 1st quarter. Principal Financial Group Inc. now owns 19,946 shares of the biotechnology company’s stock worth $1,478,000 after buying an additional 530 shares in the last quarter. Fuller & Thaler Asset Management Inc. lifted its position in shares of Sarepta Therapeutics by 0.5% during the 2nd quarter. Fuller & Thaler Asset Management Inc. now owns 145,854 shares of the biotechnology company’s stock worth $19,279,000 after buying an additional 709 shares in the last quarter. SeaCrest Wealth Management LLC lifted its position in shares of Sarepta Therapeutics by 59.0% during the 2nd quarter. SeaCrest Wealth Management LLC now owns 2,326 shares of the biotechnology company’s stock worth $307,000 after buying an additional 863 shares in the last quarter. Finally, Commonwealth Equity Services LLC lifted its position in shares of Sarepta Therapeutics by 11.0% during the 2nd quarter. Commonwealth Equity Services LLC now owns 8,989 shares of the biotechnology company’s stock worth $1,188,000 after buying an additional 892 shares in the last quarter. 90.01% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Featured Article: Day Trading

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.